ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

FAB Fusion Antibodies Plc

3.50
0.10 (2.94%)
Last Updated: 12:19:55
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.10 2.94% 3.50 3.40 3.60 3.55 3.40 3.40 901,422 12:19:55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.29 3.24M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.40p. Over the last year, Fusion Antibodies shares have traded in a share price range of 2.90p to 9.375p.

Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3.24 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.29.

Fusion Antibodies Share Discussion Threads

Showing 4101 to 4123 of 4200 messages
Chat Pages: 168  167  166  165  164  163  162  161  160  159  158  157  Older
DateSubjectAuthorDiscuss
03/7/2024
09:21
If I had a spare penny I would be adding this is targeted and manipulated on peanut sells
bigjock36
03/7/2024
09:04
Anyone topping up?
sammyshares
03/7/2024
08:54
Has to really.
sammyshares
03/7/2024
08:37
Bounce on the cards now
soultrading
02/7/2024
20:10
troutisout,

I have DM'd you the Allenby broker forecasts. But my apologies my wording was imprecise, "in 20024" should be "in the year to 31 Dec 2024", there are no forecasts available beyond that.

What words/numbers in the 30 April 2024 Year-end trading statement make you think that "FAB have turned a corner"?



I note:

"Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues"

However:

1. This was the first time that FAB published a number for their pipeline so it's impossible to tell if this represents an improvement on the prior period and hence evidence of having "turned a corner"?

2. The gross margin in the year to 31 March 2023 was 19.8% and admin costs are in the ball park of £3m per annum. That means that FAB has to get to a revenue of c. £15m in order to just break even. Ie:

(£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000Profit for the period £ 0



I have assumed a 20% gross profit margin to keep the numbers simple.

If FAB don't get to a revenue of £15m then they will make a loss in the year to 31 March 2025. Furthermore, if FAB don't get to half of that revenue number (£7,500k) then FAB will burn through their current cash and need to raise funds again.

What forecast full-year revenue for 2025 do you infer from the 30 April 2024 Year-end trading statement?

JakNife

jaknife
02/7/2024
18:12
"So current forecasts for 2024 are that revenue will be 28% *DOWN* on 2023 revenue, continuing a negative trend. Those same forecasts are for continued losses in 2024."

Are you able to provide some evidence of current forecasts for continued losses in 2024???
Only FY 2024 ended at the end of March, the last few months are now FY2025, so you seem behind the curve and yes there is an Trading Update RNS from 30th April that suggests FAB have turned a corner and the last months of FY 2024 were the highest earning of that trading year.

troutisout
02/7/2024
11:47
bobaxe1,

"Oversold company
Turned a corner
Should re rate"

Do you have anything to demonstrate that FAB has "turned a corner"?

It's just that I noted here a while ago that the recent trend of revenue performance is:


2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024E £1.14m



So current forecasts for 2024 are that revenue will be 28% *DOWN* on 2023 revenue, continuing a negative trend. Those same forecasts are for continued losses in 2024.

Have I missed an RNS that demonstrates that FAB has "turned a corner"? Are forecasts for 2025 materially higher? Is 2025 finally going to be a profitable year? Where is the objective evidence please?

JakNife

jaknife
02/7/2024
11:37
Oversold company Turned a corner Should re rate
bobaxe1
23/6/2024
12:17
THE PASTI think you are right, the way I see it is that the company went through a tough period, caused by being too focused on a particular area, and client base. This focused client base was highly dependent on a constant flow of venture capital. When VC dropped off across the board, the smaller companies (fusions clients) had to put projects on hold and therefore so did fusion.This put fusion in a difficult place and led to a need for fusion to raise capital during very unfavourable market conditions.The combination of these two issues caused a massive fall in share price and rightly so, which was not good for existing shareholders.SURVIVE MODEThe board addressed these issues by reducing out goings, headcount and the directors agreed to be paid in shares.They also diversified their client base to include venture capital but also blue chip organisations, research clientele, and branched into other areas such as veterinary. They also have started a royalty program to achieve on going working capital.This was a smart and needed move as it eliminates the past from reoccurring. THRIVE MODETo achieve this the company has been heavily promoting itself in the industry and signed with huge companies and organisations some of which are in the billionaire bracket as a result.The smart speculation is that one very large antibody company has also signed a test contract with the purpose of branching into the therapeutic area. This is a gateway which could open many partnerships for both companies.And of course having signed with USA Cancer research to validate their OPTIMAL at zero cost.INVESTMENT CASEThis is a recovery trade at these levels. But one that has been derisked heavily now and provides an almost unbelievable opportunity to buy cheap stock, The current share price is not attributing any value to fusions, tech, Intellectual property or the changes the company have made in their outgoings, cash position, royalties, grants, or stronger portfolio base.They are fully funded into 2025 and like to be cash neutral to positive this year. They have a working pipeline of sales which is converting to revenues and growing fast. The board are seeing a marked improvement across the sector and from the recent interviews it suggests the company has already turned a corner and are doing well.I don't think opportunities like this come along very often and it is certainly a buy and hold trade which could lead to a huge increase in value,
soultrading
22/6/2024
12:22
Bigjock36,

"The business is recovering we have been through all this before it's like a broken record with these clowns"

It would help if you could point to real figures to justify your point. For example, here is the recent track record of revenue:

2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024e £1.14m



These don't illustrate a recovering business, they illustrate a business in terminal decline!

JakNife

jaknife
21/6/2024
18:39
The business is recovering we have been through all this before it's like a broken record with these clownsJak nife and your alter ego clock tower work in tandem as you can see with there posts concurring at the same time Month in month outAlways easy to shoot down a business which is recovering
bigjock36
20/6/2024
16:00
They also do paid services by the looks of things although they are keeping costs low…
gtc1508
20/6/2024
15:24
"Powered by Bitrix24 — Free websites and CRM"
millennialinvestor
20/6/2024
13:10
Something brewing here - they are working on a new website in privateCheck this out hTTps://optimal.fusionantibodies.com/
soultrading
20/6/2024
09:52
Turning back up it seems
soultrading
19/6/2024
16:30
How long may it be before this delists, if they need further funds, and cannot access them.
clocktower
18/6/2024
08:46
City Whispers speculate that the recent household name might be considering a take over bid
sammyshares
17/6/2024
09:59
Slow day so far
soultrading
13/6/2024
15:49
Guess we will see, Always better to play the ball rather than the player, but I guess the kids of today were raised different,
soultrading
13/6/2024
11:34
BB police arrived
bobaxe1
13/6/2024
11:25
Not difficult to check your history on here of poor predictions
inaminute
13/6/2024
09:20
Looks like a move back to 4
soultrading
12/6/2024
10:04
https://x.com/fsnantibodies/status/1800815301862506919?s=61
soultrading
Chat Pages: 168  167  166  165  164  163  162  161  160  159  158  157  Older

Your Recent History

Delayed Upgrade Clock